Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL6 | Q9H5J4 | 18/20 | 0.62 |
| ▸ | ELOVL3 | Q9HB03 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889039 | 1.00 | ELOVL6 (0.62) | ELOVL6ELOVL3GLAMEN1ALDH1A1 | |
| SCHEMBL3409748 | 0.87 | ELOVL6 (0.56) | ELOVL6ELOVL3TP53 | |
| SCHEMBL2891035 | 0.80 | ELOVL6 (0.70) | ELOVL6ELOVL3 | |
| SCHEMBL2891037 | 0.80 | ELOVL6 (0.70) | ELOVL6ELOVL3 | |
| SCHEMBL2883519 | 0.79 | ELOVL6 (0.70) | ELOVL6ELOVL3LMNA | |
| SCHEMBL2883518 | 0.79 | ELOVL6 (0.70) | ELOVL6ELOVL3LMNA | |
| SCHEMBL2883425 | 0.77 | ELOVL6 (1.00) | ELOVL6 | |
| SCHEMBL2883427 | 0.77 | ELOVL6 (1.00) | ELOVL6 | |
| SCHEMBL2889085 | 0.75 | ELOVL6 (0.71) | ELOVL6ELOVL3ALDH1A1 | |
| SCHEMBL2889082 | 0.75 | ELOVL6 (0.71) | ELOVL6ELOVL3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2261210-B1 | 3-SUBSTITUTED SULFONYL PIPERAZINE DERIVATIVE | MSD KK (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-8367698-B2 | 3-substituted sulfonyl piperidine derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120232109-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | NAGASE TSUYOSHI (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8188280-B2 | 3-substituted sulfonyl piperidine derivative | MSD K.K. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100331360-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | MSD K.K. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331360-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | H1-3, H1-0, H1-2 | ELOVL6 1777/4885ELOVL3 1564/4885GLA 1883/4885 |
| US-20120232109-A1 | 3-SUBSTITUTED SULFONYL PIPERIDINE DERIVATIVE | H1-3, H1-0, H1-2 | ELOVL6 1777/4885ELOVL3 1564/4885GLA 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.